Figure 2.

Immunoreactivity for p63, α-SMA, E-cadherin and Ki-67 in in situ and invasive areas. Difference between in situ and invasive areas for p63 and α-SMA (a) and e-cadherin (b) demonstrated by immunohistochemistry. Accumulation of versican in invasive carcinomatous areas when compared to in situ areas (c). *Spearman correlation. §Wilcoxon test.